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Abstract 
Purpose: To prepare some 2-amino-4-(7-substituted/unsubstitutedcoumarin-3-yl)-6-(chlorosubstitute 
dphenyl) pyrimidines as antimicrobial agents. 
Methods: Some 2-amino-4-(7-substituted/unsubstitutedcoumarin-3-yl)-6-(chlorosubstitutedphenyl) 
pyrimidines were prepared by reacting 3-chlorosubstitutedphenyl-1-(7-substituted/unsubstituted 
coumarin-3-yl)prop-2-ene-1-ones with guanidine carbonate. The chemical structures of the synthesized 
compounds were elucidated by Fourier transform infra-red spectroscopy (FTIR), 1H-nuclear magnetic 
resonance (1H-NMR), mass spectrometry and elemental analysis. The synthesized compounds were 
investigated for their antimicrobial activity against four bacteria and five fungi by serial plate dilution 
method using ofloxacin and ketoconazole as reference antimicrobial drugs, respectively, and their 
minimum inhibitory concentrations (MICs) were determined. 
Results: Compounds 1 (p < 0.0001), 2 (p < 0.0001), 6 (p < 0.0001) and 8 (p < 0.0001) were the most 
active antibacterial agents among the synthesized compounds compared to control and standard 
agents. Structure-activity relationship revealed that substitution of chlorine atoms at 2- and 6- positions 
of the phenyl ring are critical for antibacterial activity in the case of dichlorophenyl derivatives, while for 
monochlorophenyl derivatives, the positions 2 and 4 of the phenyl ring were critical for antibacterial 
activity. None of the compounds exhibited comparable antifungal activity to the standard antifungal 
drug, ketoconazole, even at high concentrations. 
Conclusion: It is evident that the synthesized compounds are relatively very active antibacterial agents 
but are weak antifungal agents. However, these compounds need further evaluation of their 
antibacterial activity against other bacterial strains to ascertain their broad spectrum antibacterial 
activity.  
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Microbial infections have been problematic for 
humans over the centuries. A large number of 
antimicrobial agents have been developed by 
scientists to combat microbial infection 
challenges. However, because of the emergence 
of new microbial infections and the development 
of antibiotic resistance, these infections still pose 
serious threats to patients. According to 
literature, about 40 new microbial infections have 
been discovered since 1970s; more than 2 
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million American people are affected by antibiotic 
resistance and about 23000 American patients 
die annually due to the development of antibiotic 
resistance. Therefore, there is a need to develop 
new drugs continuously for the treatment of 
microbial infections [1]. 
 
Pyrimidine derivatives have an important place in 
medicinal chemistry as these are associated with 
a broad range of biological activities [2,3] 
including antimicrobial activity [4-7]. Recently, the 
significance and biological importance of 
pyrimidine derivatives including their clinical 
applications in the microbial world has been 
reviewed [8]. The antimicrobial activity of 
pyrimidine derivatives against broad range of 
microbes makes it an important skeleton in 
medicinal chemistry and drug development 
against microbes. Encouraged by these 
observations and also in continuation of our 
search for potent antimicrobial agents [9-16] 
including antimicrobial agents having coumarin 
moiety [16,17], the aim of this study was to 
prepare some 2-amino-4-(7-
substituted/unsubstitutedcoumarin-3-yl)-6-
(chlorosubstitutedphenyl) pyrimidines in order to 






Melting points were measured in open capillary 
tubes and are uncorrected. IR (KBr) spectra were 
recorded on a Nicolet, 5PC FT-IR spectrometer 
(Browser Morner, USA) and 1H-NMR spectra on 
a Bruker DRX-300 FT NMR (Bruker, Germany) 
spectrophotometer using TMS as internal 
reference (chemical shift in δ ppm). Mass spectra 
were recorded on a Jeol-JMS-D-300 mass 
spectrometer (70 eV) (Jeol, Japan). Satisfactory 
analysis for C, H, and N was obtained for the 
compounds within ± 0.4 % of the theoretical 
values. Purity of the compounds was checked on 
silica gel G plates using iodine vapours as 
visualizing agent. Rf value of the compounds 
was determined by using a mixture of benzene 
and acetone (9:1). All reagents used in the 
present work were of analytical grade.  The 2-
amino-4-(7-substituted/unsubstitutedcoumarin-3-
yl)-6-(chlorosubstitutedphenyl)pyrimidines (1-18) 
were prepared according to the method outlined 
in Scheme 1. 
 
Appropriate salicyldehydes (X = H, Cl, Br) were 
reacted with ethyl acetoacetate in the presence 
of piperidine using ethanol as solvent to obtain 7-
substituted/unsubstituted-3-acetylcoumarins. 
 
These acetyl coumarins were then reacted with 
different chlorosubstituted benzaldehydes in the 
presence of piperidine using absolute ethanol as 
solvent to obtain 3-chlorosubstitutedphenyl-1-(7-
substituted/unsubstitutedcoumarin-3-yl)prop-2-
ene-1-ones, .i.e., chalcones. These chalcones 
were cyclised with guanidine carbonate using 
































X = H, Cl, Br
X = H, Cl, Br
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General method for the synthesis of 7-
substituted/unsubstituted-3-acetylcoumarins 
 
A mixture of appropriate salicyldehyde (0.02 
moles) and ethyl acetoacetate (0.02 moles) in 30 
mL of ethanol was taken in a 100 mL round 
bottom flask. To this mixture, 3 to 5 drops of 
piperidine were added. The reaction mixture was 
refluxed for 1 h to 2 h. The resulting mass was 
kept at room temperature for 30 min and poured 
on crushed ice. The solid separated was filtered, 
dried and recrystallized from ethanol [16,17]. 
 





Equimolar quantity of 7-
substituted/unsubstituted-3-acetylcoumarin and 
appropriate chlorosubstituted benzaldehyde was 
refluxed in absolute ethanol using piperidine as 
catalyst for 6 h to 10 h. The solution mixture was 
concentrated, cooled and poured on crushed ice. 
The compound obtained was filtered at pump, 
dried and recrystallized from ethanol [16,17]. 
 





A mixture of appropriate 3-chlorosubstitute 
dphenyl-1-(7-substituted/unsubstitutedcoumarin-
3-yl) prop-2-ene-1-one (0.01 moles) and 
guanidine carbonate (0.015 moles) was refluxed 
in ethanol for 8 - 10 h. The resulting mass was 
evaporated to dryness and the product obtained 
was washed with water repeatedly and then 
recrystallized from ethanol. The purity of the 
compounds was established on the basis of TLC.  
 
Evaluation of antimicrobial activity 
 
All the synthesized compounds, 2-amino-4-(7-
substituted/unsubstitutedcoumarin-3-yl)-6-
(chlorosubstitutedphenyl) pyrimidines (1-18), 
were tested for their in vitro antimicrobial activity 
by serial plate dilution method [18,19] against 
Gram-positive bacteria, Staphylococcus aureus 
(ATCC-25923); Gram-negative bacteria, 
Escherichia coli (ATCC-25922), Pseudomonas 
aeruginosa (ATCC-27853) and Klebsiella 
pneumoniae (ATCC-700603); and fungi, Candida 
albicans (ATCC-2091), Aspergillus niger (MTCC-
281), Aspergillus flavus (MTCC-277), Monascus 
purpureous (MTCC-369) and Penicillium citrinum 
(NCIM-768). Nutrient agar medium and 
Sabouraud dextrose medium were used for 
antibacterial activity and antifungal activity, 
respectively. The synthesized compounds were 
tested at concentrations of 200, 100, 50, 25 and 
12.5 μg/mL. The reference or standard antibiotic, 
ofloxacin and ketoconazole were used at 50, 25 
and 12.5 μg/mL concentrations for antibacterial 
activity and antifungal activity, respectively. 
Sterile dimethyl sulfoxide (DMSO) was used for 
the preparation of desired concentrations of the 
synthesized compounds and standard antibiotics.  
Sterile dimethyl sulfoxide without the synthesized 
compounds and standard antibiotics served as 
negative control. The minimum inhibitory 
concentrations (MICs) values of the synthesized 
compounds, ofloxacin and ketoconazole were 
also determined. The minimum inhibitory 
concentration (MIC) has been defined as the 
lowest concentration of a compound that 





All the data are presented as mean ± standard 
deviation (SD) and were analyzed by one-way 
analysis of variance (ANOVA) with Dunnett's 
multiple comparison test using GraphPad Prism 
version 5.00 for Windows (GraphPad Software, 
San Diego California USA). The results were 
considered significantly different at p < 0.05 





The physical constants of the title compounds 
are provided in Table 1. 
 
FTIR, 1H-NMR, mass and elemental analysis 






IR (KBr) cm-1: 3431 (N-H), 1712 (C=O), 1612 
(C=N), 1545 (C=C), 1133 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.38 (bs, 2H, NH2, 
exchangable with D2O), 7.05 (d, J = 12Hz, 2H, 
Ar-H), 7.26 (m, 3H, Ar-H), 7.48 (t, J = 8Hz, 2H, 
Ar-H), 7.61 (s, 1H, Ar-H), 7.84 (d, J = 12Hz, 2H, 
Ar-H); Elemental Analysis (C19H12N3O2Cl), Found 
% (Calculated %): C, 65.22 (65.24); H, 3.45 
(3.46); N, 12.00 (12.01); Mass (m/z): 349 (M+), 
350 (M+ + 1). 
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(1 - 18)  
 




MP (oC) Rf 
value 
1 4-Chlorophenyl H C19H12N3O2Cl 349.77 55 165-167 0.74 
2 2,6-Dichlorophenyl H C19H11N3O2Cl2 384.21 48 180-182 0.71 
3 2,4-Dichlorophenyl H C19H11N3O2Cl2 384.21 45 151-153 0.71 
4 2-Chlorophenyl H C19H12N3O2Cl 349.77 45 173-175 0.68 
5 4-Chlorophenyl Cl C19H11N3O2Cl2 384.21 50 160-162 0.71 
6 4-Chlorophenyl Br C19H11N3O2ClBr 428.66 47 147-149 0.66 
7 2,6-Dichlorophenyl Cl C19H10N3O2Cl3 418.66 52 163-165 0.65 
8 2,6-Dichlorophenyl Br C19H10N3O2Cl2Br 463.11 45 150-152 0.64 
9 2,4-Diclorophenyl Cl C19H10N3O2Cl3 418.66 50 171-173 0.69 
10 2,4-Diclorophenyl Br C19H10N3O2Cl2Br 463.11 46 160-162 0.62 
11 2-Chlorophenyl Cl C19H11N3O2Cl2 384.21 50 187-189 0.72 
12 2-Chlorophenyl Br C19H11N3O2ClBr 428.66 50 164-166 0.74 
13 2,5-Dichlorophenyl Cl C19H10N3O2Cl3 418.66 40 141-143 0.66 
14 2,5-Dichlorophenyl Br C19H10N3O2Cl2Br 463.11 43 155-157 0.70 
15 3,5-Dichlorophenyl Cl C19H10N3O2Cl3 418.66 42 172-174 0.68 
16 3,5-Dichlorophenyl Br C19H10N3O2Cl2Br 463.11 48 165-177 0.65 
17 3,4-Dichlorophenyl Cl C19H10N3O2Cl3 418.66 45 149-151 0.69 
18 3,4-Dichlorophenyl Br C19H10N3O2Cl2Br 463.11 40 174-176 0.71 





IR (KBr) cm-1: 3431 (N-H), 1717 (C=O), 1611 
(C=N), 1545 (C=C), 1130 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.36 (bs, 2H, NH2, 
exchangable with D2O), 7.08 (d, J = 12Hz, 2H, 
Ar-H), 7.22-7.48 (m, 4H, Ar-H), 7.61 (s, 1H, Ar-
H), 7.7 (d, J = 12Hz, 2H, Ar-H); Elemental 
Analysis (C19H11N3O2Cl2), Found % (Calculated 
%): C, 59.38 (59.39); H, 2.88 (2.89); N, 10.92 





IR (KBr) cm-1: 3425 (N-H), 1715 (C=O), 1611 
(C=N), 1545 (C=C), 1133 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.34 (bs, 2H, NH2, 
exchangable with D2O), 7.06 (d, J = 12Hz, 2H, 
Ar-H), 7.26-7.75 (m, 6H, Ar-H), 7.94 (s, IH, Ar-H); 
Elemental Analysis (C19H11N3O2Cl2), Found % 
(Calculated %): C, 59.37 (59.39); H, 2.88 (2.89); 





IR (KBr) cm-1: 3430 (N-H), 1718 (C=O), 1613 
(C=N), 1539 (C=C), 1130 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.35 (bs, 2H, NH2, 
exchangable with D2O), 7.06 (d, J = 12Hz, 2H, 
Ar-H), 7.29-7.80 (m, 8H, Ar-H); Elemental 
Analysis (C19H12N3O2Cl), Found % (Calculated 
%): C, 65.22 (65.24); H, 3.45 (3.46); N, 12.00 





IR (KBr) cm-1: 3428 (N-H), 1719 (C=O), 1612 
(C=N), 1540 (C=C), 1132 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.32 (bs, 2H, NH2), 
7.10-7.45 (m, 6H, Ar-H), 7.61 (s, 1H, Ar-H), 7.84 
(d, J = 12Hz, 2H, Ar-H); Elemental Analysis 
(C19H11N3O2Cl2), Found % (Calculated %): C, 
59.38 (59.39); H, 2.88 (2,89); N, 10.93 (10.94); 
Mass (m/z): 384 (M+), 385 (M+ + 1). 
 
Imran et al 





IR (KBr) cm-1: 3426 (N-H), 1718 (C=O), 1609 
(C=N), 1543 (C=C), 1130 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.37 (bs, 2H, NH2), 
7.15-7.48 (m, 6H, Ar-H), 7.69 (s, 1H, Ar-H), 7.80 
(d, J = 12Hz, 2H, Ar-H); Elemental Analysis 
(C19H11N3O2ClBr), Found % (Calculated %): C, 
53.22 (53.24); H, 2.58 (2.59); N, 9.78 (9.80); 





IR (KBr) cm-1: 3426 (N-H), 1716 (C=O), 1608 
(C=N), 1544 (C=C), 1134 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.38 (bs, 2H, NH2), 
7.15-7.88 (m, 8H, Ar-H); Elemental Analysis 
(C19H10N3O2Cl3), Found % (Calculated %): C, 
54.50 (54.51); H, 2.40 (2.41); N, 10.03 (10.04); 





IR (KBr) cm-1: 3427 (N-H), 1717 (C=O), 1607 
(C=N), 1544 (C=C), 1132 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.34 (bs, 2H, NH2), 
7.10-7.85 (m, 8H, Ar-H); Elemental Analysis 
(C19H10N3O2Cl2Br), Found % (Calculated %): C, 
49.27 (49.28); H, 2.17 (2.18); N, 9.05 (9.07); 






IR (KBr) cm-1: 3427 (N-H), 1718 (C=O), 1608 
(C=N), 1540 (C=C), 1132 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.38 (bs, 2H, NH2), 
7.13-7.83 (m, 8H, Ar-H); Elemental Analysis 
(C19H10N3O2Cl3), Found % (Calculated %): C, 
54.50 (54.51); H, 2.40 (2.41); N, 10.02 (10.04); 





IR (KBr) cm-1: 3429 (N-H), 1717 (C=O), 1611 
(C=N), 1543 (C=C), 1133 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.38 (bs, 2H, NH2), 
7.13-7.83 (m, 8H, Ar-H); Elemental Analysis 
(C19H10N3O2Cl2Br), Found % (Calculated %): C, 
49.27 (49.28); H, 2.17 (2.18); N, 9.06 (9.07); 





IR (KBr) cm-1: 3427 (N-H), 1718 (C=O), 1607 
(C=N), 1542 (C=C), 1130 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.34 (bs, 2H, NH2), 
7.19-7.90 (m, 9H, Ar-H); Elemental Analysis 
(C19H11N3O2Cl2), Found % (Calculated %): C, 
59.38 (59.39); H, 2.88 (2.89); N, 10.92 (10.94); 





IR (KBr) cm-1: 3425 (N-H), 1718 (C=O), 1608 
(C=N), 1545 (C=C), 1130 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.36 (bs, 2H, NH2), 
7.15-7.84 (m, 9H, Ar-H); Elemental Analysis 
(C19H11N3O2ClBr), Found % (Calculated %): C, 
53.22 (53.24); H, 2.58 (2.59); N, 9.78 (9.80); 






IR (KBr) cm-1: 3435 (N-H), 1715 (C=O), 1610 
(C=N), 1535 (C=C), 1132 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.33 (bs, 2H, NH2), 
7.16-7.88 (m, 8H, Ar-H); Elemental Analysis 
(C19H10N3O2Cl3), Found % (Calculated %): C, 
54.50 (54.51); H, 2.40 (2.41); N, 10.03 (10.04); 





IR (KBr) cm-1: 3434 (N-H), 1718 (C=O), 1611 
(C=N), 1531 (C=C), 1136 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.35 (bs, 2H, NH2), 
7.10-7.81 (m, 8H, Ar-H); Elemental Analysis 
(C19H10N3O2Cl2Br), Found % (Calculated %): C, 
49.27 (49.28); H, 2.16 (2.18); N, 9.06 (9.07); 





IR (KBr) cm-1: 3433 (N-H), 1713 (C=O), 1616 
(C=N), 1534 (C=C), 1133 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.37 (bs, 2H, NH2), 
7.15-7.89 (m, 8H, Ar-H); Elemental Analysis 
(C19H10N3O2Cl3), Found % (Calculated %): C, 
54.50 (54.51); H, 2.40 (2.41); N, 10.03 (10.04); 
Mass (m/z): 418 (M+), 419 (M+ + 1). 
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IR (KBr) cm-1: 3429 (N-H), 1719 (C=O), 1612 
(C=N), 1540 (C=C), 1136 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.34 (bs, 2H, NH2), 
7.15-7.81 (m, 8H, Ar-H); Elemental Analysis 
(C19H10N3O2Cl2Br), Found % (Calculated %): C, 
49.27 (49.28); H, 2.16 (2.18); N, 9.06 (9.07); 





IR (KBr) cm-1: 3432 (N-H), 1720 (C=O), 1611 
(C=N), 1537 (C=C), 1134 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.37 (bs, 2H, NH2), 
7.13-7.86 (m, 8H, Ar-H); Elemental Analysis 
(C19H10N3O2Cl3), Found % (Calculated %): C, 
54.51 (54.51); H, 2.40 (2.41); N, 10.04 (10.04); 





IR (KBr) cm-1: 3433 (N-H), 1717 (C=O), 1614 
(C=N), 1533 (C=C), 1134 (C-O-C); 1H-NMR 
(CDCl3, DMSO-d6)  ppm: 5.35 (bs, 2H, NH2), 
7.14-7.88 (m, 8H, Ar-H); Elemental Analysis 
(C19H10N3O2Cl2Br), Found % (Calculated %): C, 
49.28 (49.28); H, 2.17 (2.18); N, 9.07 (9.07); 




Antimicrobial activity of the title compounds was 
investigated against one Gram-positive bacteria, 
S. aureus; three Gram-negative bacteria, E. coli, 
P. aeruginosa, and K. pneumoniae; and five 
fungi, C. albicans, A. niger, A. flavus, M. 
purpureous and P. citrinum. The antibacterial 
activity and antifungal activity data are presented 




A total of eighteen 2-amino-4-(7-substituted/ 
unsubstitutedcoumarin-3-yl)-6-(chlorosubstatute 
dphenyl) pyrimidines (1-18) were prepared as 
antimicrobial agents. The chemical structures of 
these compounds were confirmed by IR, 1H-
NMR, mass spectrometry and elemental analysis 
data. Cyclisation of the chalcones to the title 
compounds was confirmed by the appearance of 
IR absorption peaks  from 3425 to 3435 cm-1 due 
to the stretching vibration of N-H of -NH2 group 
and the appearance of IR absorption peaks from 
1607 to 1616 cm-1 due to the stretching vibration 
of C=N group in the title compounds. The 
presence of -NH2 group in the title compounds 
was supported by the appearance of broad 
singlets at δ (ppm) values from 5.33 to 5.38 in 
the 1H-NMR spectrum.  
 




Zone of inhibition, mm (minimum inhibitory concentration, μg/mL) 
S. aureus E. coli P. aeruginosa K. pneumoniae 
     
1 22.05±0.13a (50) 23.15±0.06a (50) 17.08±0.05a (25) 20.08±0.05a (25) 
2 18.03±0.13a (25) 17.95±0.10a (50) 28.08±0.05a (12.5) 19.03±0.05a (25) 
3 13.95±0.13a (25) 20.90±0.08a (50) 19.95±0.06a (50) 15.95±0.06a (100) 
4 4.95±0.13a (200) 15.98±0.10a (50) 16.05±0.06a (25) 12.93±0.05a (25) 
5 19.95±0.13a (50) 13.08±0.05a (50) 7.95±0.10a (200) 8.08±0.05a (100) 
6 20.08±0.13a (25) 24.9±0.08a (50) 23.1±0.14a (25) 18.95±0.06a (25) 
7 9.9±0.08a (100) 16.95±0.06a (50) 18.05±0.06a (25) 8.88±0.05a (50) 
8 21.9±0.08a (50) 16.08±0.13a (50) 27.95±0.06a (25) 17.98±0.05a (25) 
9 11.03±0.10a (100) 5.90±0.05a (200) 6.95±0.06a (200) 7.13±0.05a (200) 
10 9.98±0.10a (50) 14.90±0.05a (25) 14.90±0.05a (50) 6.93±0.05a (100) 
11 12.93±0.05a (50) 13.13±0.05a (25) 11.0±0.08a (50) 6.15±0.06a (100) 
12 7.15±0.06a (200) 7±0.08a (200) 6.05±0.06a (200) 4.98±0.10a (200) 
13 5.98±0.10a (200) 8.08±0.05a (200) 9.88±0.05a (100) 8.0±0.08a (50) 
14 17.98±0.10a (50) 13.95±0.10a (25) 14.03±0.05a (50) 20.0±0.08a (25) 
15 4±0.08a (200) 5.13±0.05a (200) 6.95±0.06a (200) 4.1±0.08a (200) 
16 5.05±0.10a (200) 6.05±0.06a (200) 5.98±0.05a (200) 6.03±0.10a (200) 
17 16.15±0.06a (50) 19.05±0.06a (25) 9.95±0.06a (50) 9.93±0.05a (50) 
18 12.1±0.08a (25) 20.03±0.15a (50) 21.95±0.06a (25) 18.03±0.05a (50) 
Ofloxacin 24.08±0.05a (25) 27.95±0.06a (12.5) 31.05±0.06a (12.5) 30.03±0.10a (12.5) 
Negative control  0.0 0.0 0.0 0.0 
The values in parenthesis represent the corresponding MIC (μg/mL); ap < 0.0001 
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Table 3: Antifungal activity data of the title compounds (1-18) 
 
Compound Zone of inhibition, mm (minimum inhibitory concentration, μg/mL) 























9.98±0.05a (50) 13.98±0.05a (50) 11.98±0.05a 
(50) 




9.93±0.05a (100) 11.08±0.05a 
(100) 
5 20.05±0.1a (50) 16.05±0.06a 
(50) 








14.03±0.05a (50) 17.15±0.06a 
(50) 




































































9.05±0.06a (200) 11.95±0.06a 
(50) 




































0.0 0.0 0.0 0.0 0.0 
Values in parenthesis represent the corresponding MIC (μg/mL); ap < 0.0001 
 
The presence of IR absorption peaks from 1712 
to 1720 cm-1 due to the presence of C=O group 
and IR absorption peaks from 1130 to 1136 cm-1 
due to the presence of C-O-C group supported 
the coumarin moiety. The 1H-NMR spectra also 
confirmed the required number of H-atoms of the 
title compounds. Furthermore, the elemental 
analysis and molecular ion peaks of the title 
compounds were consistent with the assigned 
structures. 
 
The results of the antibacterial activity revealed 
that ofloxacin showed its MIC against S. aureus 
at 25 μg/mL concentration, and MIC against E. 
coli, P. aeruginosa, and K. pneumonia at 12.5 
μg/mL. Most of the title compounds did not 
display comparable antibacterial activity to 
ofloxacin at 25 and 12.5 μg/mL concentrations. 
However, some of the title compounds displayed 
comparable antibacterial activity to ofloxacin at 
higher concentrations with high statistically 
significant results as compared to control group 
and standard drug group. Compound 1 (X = H; 
Ar = 4-chloropheny; p < 0.0001) and compound 8 
(X = Br; Ar = 2,6-dichlorophenyl; p < 0.0001) 
showed comparable activity to ofloxacin against 
S. aureus at 50 μg/mL concentration. Compound 
6 (X = Br; Ar = 4-chlorophenyl; p < 0.0001) 
showed comparable activity to ofloxacin against 
E. coli at 50 μg/mL concentration. Compound 2 
(X = H; Ar = 2,6-dichlorophenyl; p < 0.0001) and 
compound 8 (X = Br; Ar = 2,6-dichlorophenyl; p < 
0.0001) showed comparable activity to ofloxacin 
against P. aeruginosa at 12.5 and 25 μg/mL 
concentrations, respectively. None of the 
compounds exhibited comparable activity to 
Imran et al 
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ofloxacin against K. pneumonia even at higher 
concentrations. The results of antifungal activity 
revealed that ketoconazole showed MIC of 12.5 
μg/mL against C. albicans, A. niger and M. 
purpureous at concentration, and of 25 μg/mL 
against A. flavus and P. citrinum. None of the title 
compounds exhibited comparable antifungal 





It is evident that the synthesized compounds are 
relatively very active antibacterial agents but 
display weak antifungal activity. However, these 
compounds need further evaluation of their 
antibacterial activity against other bacterial 
strains to ascertain their broad spectrum 
antibacterial profile. It is possible too that 
modification of the compound structures will 
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